Not only Effient present sales are gloomy, its future looks even worse especially if brilinta is approved, as you've noted #msg-41731834. The platelet function test - VerifyNow holds a slim chance to increases the use of Effient, imo.
I hardly believe that accumetrics can help anyone to make more business. If they knew how to do this they would have started with themselves.
Accumetrics has already burned 68 Mn USD since 2003, their test is simply too expensive to be used in routine.
Most likely Accumetrics will run out of cash at the end of the year anyway, but perhaps Lilly will purchase them to keep the company running. Perhaps their only chance.
Market Data 
Markets 
AI
